Anti-JC Virus Antibodies: Implications for PML Risk Stratification

Annals of Neurology

Volumn 68, Issue 3, 2010, Pages 295-303

  Gorelik, Leonid ^a   Lerner, Michaela ^a   Bixler, Sarah ^a   Crossman, Mary ^a   Schlain, Brian ^a   Simon, Kenneth ^a   Pace, Amy ^a   Cheung, Anne ^a   Chen, Ling Ling ^a   Berman, Melissa ^a   Zein, Fairuz ^a   Wilson, Ewa ^a   Yednock, Ted ^b   Sandrock, Alfred ^a   Goelz, Susan E ^a   Subramanyam, Meena ^a  

^a BIOGEN   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NATALIZUMAB; VIRUS ANTIBODY; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; VIRUS DNA;

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; URINALYSIS; DIAGNOSTIC USE; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PROCEDURES; RISK FACTOR; VIRUS LOAD;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RISK FACTORS; VIRAL LOAD; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956387401     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22128     Document Type: Article

References (31)

1. Agostini H, Ryschkewitsch C, Singer E, et al. Co-infection with two JC virus genotypes in brain, cerebrospinal fluid or urinary tract detected by direct cycle sequencing of PCR products. J Neurovirol 1996;2:259-267. (Pubitemid 26285270)
2. Chesters P, Heritage J, McCance D. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 1983;147:676-684. (Pubitemid 13088241)
3. Heritage J, Chesters P, McCance D. The persistence of papovavirus BK DNA sequences in normal human renal tissue. J Med Virol 1981;8:143-150. (Pubitemid 12247609)
4. Major E. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
5. Pietropaolo V, Videtta M, Fioriti D, et al. Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol 2003;9:603-611. (Pubitemid 37536716)
6. Sunyaev S, Lugovskoy A, Simon K, et al. Adaptive mutation in the JC virus protein capsid are associated with progressive multifocal leukoencephelopathy (PML). PLoS Genet 2009;5:e1000368.
7. Neff R, Hurst F, Falta E, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008;86:1474-1478.
8. Martin S, Marty F, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24. (Pubitemid 43939071)
9. Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010;91:1849-1853.
10. Carter J, Madeleine M, Wipf G, et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 2003;95:1522-1530. (Pubitemid 37322095)
11. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009;199:837-846.
12. Engels E, Rollison D, Hartge P, et al. Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer 2005;117:1013-1019. (Pubitemid 41688579)
13. Grabowski M, Viscidi R, Margolick J, et al. Investigation of prediagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients. J Med Virol 2009;81:1140-1150.
14. Kean J, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009;5:e1000363.
15. Knowles W, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-123. (Pubitemid 37121921)
16. Matos A, Duque V, Beato S, et al. Characterization of JC human polyomavirus infection in a Portugese population. J Med Virol 2010;82:494-504.
17. Padgett B, Walker D. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467-470.
18. Rollison D, Englels E, Halsey N, et al. Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2006;15:543-550.
19. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of human polyoma viruses. J Gen Virol 2003;84:1499-1504.
20. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008;57:1393-1397.
21. Kleinschmidt-DeMasters B, Tyler K. Progressive leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374. (Pubitemid 41132341)
22. Langer-Gould A, Atlas S, Green A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381. (Pubitemid 41132342)
23. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368. (Pubitemid 41132340)
24. Efron B, Tibshirani R. An introduction to the bootstrap. New York, NY: Chapman and Hall, 1993.
25. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361:1067-1074.
26. Koralnik I, Boden D, Mai V, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999;52:253-260. (Pubitemid 29059048)
27. Tornatore C, Berger J, Houff S, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992;31:454-462.
28. Rudick R, Polman C, O'Connor P, et al. Evaluation of natalizumab treatment on the presence of JC virus in blood and urine from multiple sclerosis patients. Mult Scler 2009;15(suppl):S274-S275.
29. Cubitt C, Cui X, Agostini H, et al. Predicted amino acid sequences for 100 JC strains. J Neurovirol 2001;7:339-344. (Pubitemid 32894238)
30. Clifford D, DeLuca A, Simpson D, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
31. Lindå H, von Heijne A, Major E, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-1087.